bluuebunny/crossref_metadata_2025_split huggingface dataset:
CLRM-01 DETERMINANTS OF SYMPTOMATIC INTRACRANIAL PROGRESSION FOLLOWING AN INITIAL STEREOTACTIC RADIOSURGERY COURSE
Authors: Leng Jim , Huang Christina , Qazi Jamiluddin , Carpenter David , Arshad Muzamil , Schultz Olivia , Mullikin Trey , Reitman Zachary , Kirkpatrick John , Floyd Scott , Fecci Peter , Chmura Steven , Hong Julian , Salama Joseph 
Published: August 2023

Abstract
To determine the prognostic significance of neurologic symptoms at progression for patients with brain metastases (BM) undergoing stereotactic radiosurgery (SRS), all patients completing an initial course of SRS between 1/2015 and 12/2020 were identified across two institutions. Intracranial progression (ICP) was recorded, with symptomatic ICP (SICP) defined as new/worsening neurologic symptoms without another etiology. Overall survival (OS), freedom from ICP (FFICP), and freedom from symptomatic ICP (FFSICP) were assessed via Kaplan-Meier method. For FFSICP, patients were censored at time of death or asymptomatic ICP. Logistic regression models tested parameter association to neurologic symptoms. Cox proportional hazard models tested parameters impacting FFICP and FFSICP. Among 1383 patients, median age was 63.4 years, 54.8% were female, and 45.6% had KPS ≥90. Common primary sites were non-small cell lung (48.7%), breast (14.7%), and melanoma (8.5%). 46.9% had oligometastatic disease (≤5 foci), and 53.4% had &gt;1 BM. 26.1% patients had prior surgical resection, and 10.3% had WBRT. With a median follow up of 8.7 months, 504 (36%) and 194 (14%) experienced asymptomatic and symptomatic ICP respectively. OS was worse for patients experiencing SICP (median 10.2 vs 17.9 months, p&lt;0.001). Among patients with ICP, SICP was associated with total treated tumor volume (per-ml, OR 1.01, 95% CI 1.00-1.02), while those with more recent MRI imaging and post-SRS systemic therapy was associated with asymptomatic ICP. Patients who received post-SRS chemotherapy (HR 0.64, 95% CI 0.45-0.90), immunotherapy (HR 0.49, 95% CI 0.34-0.71), or targeted therapy (HR 0.49, 95% CI 0.33-0.73) had better FFSCIP. Worse FFSCIP was associated with melanoma (HR 2.56, 95% CI 1.49-4.38), and greater than 2 BMs (HR 2.24, 95% CI 1.56-3.22). SICP is prognostic for OS, and is associated with melanoma, no systemic therapy post-SRS, and greater number of BMs. These data further support the use of SICP as a meaningful clinical endpoint.
CLRM-02 CALCIFIED SPINAL MENINGIOMAS: A SYSTEMATIC REVIEW OF CLINICAL CHARACTERISTICS, TREATMENT STRATEGIES, AND OUTCOMES
Authors: Reddy Raghuram , Shah Darsh , Palmisciano Paolo 
Published: August 2023

Abstract
Calcified meningiomas involving the spine are rare but can pose significant surgical challenges. We systematically reviewed the literature on calcified spinal meningiomas. PubMed, EMBASE, Web-of-Science, and Scopus databases were searched to include studies reporting clinical data of patients with calcified spinal meningioma. Included articles were analyzed for symptoms, imaging, spine level of the tumor, tumor location relative to the spinal cord, calcification status, treatment regimen, recurrence, progression-free survival, and outcomes. A total of 35 articles encompassing 94 patients were included. Most patients were female (90.4%), presenting with lower extremity weakness (44%) and/or lower extremity paresthesia (38.1%). Most calcified spinal meningiomas occurred in the thoracic spine (82%) and on the dorsal (33.3%) or ventral (27.2%) side relative to the spinal cord. Most tumors were intradural (87.2%). Histologically, most calcified spinal meningiomas were WHO grade I (97.4%) and psammomatous (50.7%). Most tumors demonstrated macroscopic calcification (48.9%). Most patients underwent gross total resection (91.5%) through a posterior approach (100%). Two patients (2.1%) received adjunctive radiotherapy. The most common treatment related complication was CSF leakage. Post-operatively, most patients demonstrated symptomatic improvement (75.5%) and 2 (2.1%) had local tumor recurrence. Calcified spinal meningiomas are uncommon but benign entities. These neoplasms tend to adhere to surrounding tissues and nerves and, thus, can be surgically challenging to remove. In most patients, safe gross total resection remains the standard of care, but accurate surgical planning is necessary to reduce the risks of postoperative complications.
NEIM-03 A GRADUAL INTEGRATION MODEL BASED ON MRI TO PREDICT MOLECULAR PROFILES IN PATIENTS WITH GLIOMA
Authors: Chen Hongyu , Miao Xuan , Tang Ming , Chen Zhongping , Chen Yinsheng 
Published: August 2023

Abstract
Glioma is the most common primary brain tumor. Molecular profiles, including IDH mutation, 1p/19q co-deletion, and MGMT promoter methylation, are highly correlated with the prognosis and clinical decision-making of glioma. To predict the molecular profiles from rough segmentation MRI, we developed and validated a gradual integration model. We proposed a multi-task pseudo-3D model based on rough segmented multiparametric MRI to predict molecular profiles. In this model, convolution along the depth axis was performed between convolution blocks. A total of 750 patients with glioma were retrospectively enrolled from Sun Yatsen University Cancer Center(n=576) and The Cancer Imaging Archive(n=167) to validate the performance of the framework. The model was developed and validated on the local dataset and tested on an independent external (TCIA) test set. For IDH, 1p/19q, and MGMT predictions on the TCIA set, the gradual fusion model achieves AUCs of 0.87, 0.80, and 0.71, respectively, outperforming both input or output integration models and 2D models. To conclude, our gradual fusion model demonstrated the potential to predict molecular profiles based on pre-treatment MRI. Gradual integration may be a reliable method to design 3D medical imaging models.
SDPS-36 CLINICAL PRESENTATION IS A USEFUL PROGNOSTIC MARKER IN PATIENTS WITH BRAIN METASTASES
Authors: Cacho-Díaz Bernardo , Arrieta Oscar , Gonzalez-Gonzalez Ethan 
Published: August 2023

Abstract

BACKGROUND
Brain metastases are the most common malignant intracranial tumors and a leading cause of cancer-associated death. The influence on survival of their clinical presentation is scarce.

AIM
To determine if the clinical presentation of patients with brain metastases is associated with survival.

METHODS
A retrospective database of patients with brain metastases seen at a single center from 2010 to 2022 was analyzed. Clinical presentation and its association with survival were measured individually and adjusted for other prognostic variables.

RESULTS
From 822 patients, the most common symptoms were headache 53%, focal weakness 35%, visual disorders 24%, nausea/vomiting 23%, seizures 22%, and altered mental status 18%. Clinical presentations associated with survival after multivariate analysis were no symptoms [HR 0.55 (95%CI 0.39-0.79), P = 0.001], focal weakness [HR 1.21 (95%CI 1.01-1.44), P = 0.032], altered mental status [HR 1.24 (95%CI 1.01 – 1.52), P = 0.038], and visual disorders [HR 1.29 (95%CI 1.07-1.46), P = 0.007. Adding the clinical information to the graduated prognostic score improved its prognostic performance measured by both the C-statistic and the Akaike information criteria.

CONCLUSION
Clinical symptoms should be considered in all patients with brain metastases for they are associated with outcomes.
SDPS-41 PATHOMICS AUGMENTS PREDICTIVE SURVIVAL MODELLINGIN MEDULLOBLASTOMA
Authors: Mahtabfar Aria , Familiar Ariana , Kazerooni Anahita Fathi , Kiani Mahsa , Haldar Debanjan , Viswanathan Karthik , Resnick Adam , Storm Phillip , Viaene Angela , Nabavizadeh Ali 
Published: August 2023

Abstract

PURPOSE
Medulloblastoma survival and treatment response has shown wide variability based on molecular and genomic subtyping. Early prediction of overall survival (OS) may afford clinicians an opportunity to develop individualized treatment paradigms for patients. Computational pathology (“pathomics”) confers the ability to extract sub-visual histopathologic features using high-throughput analysis to better characterize tumor biology or behavior.

METHODS
Using the Children’s Brain Tumor Network database, pediatric patients with available clinical data and whole-slide images (WSI) were evaluated for inclusion in the study. 1mm x 1mm regions-of-interest (ROI) on each H&E-stained WSI were selected to identify tumor-rich areas for subsequent pathomic analysis, and 49 quantitative pathomics features were extracted using a digital pathology software package (Qupath). LASSO cox proportional hazard model with stratified 5-fold cross-validation was used to identify high-performing features and generate risk scores. Estimated risk scores were subsequently used to stratify patients into low-, medium- and high-risk OS cohorts. Two separate models were trained including either: 1) clinical variables only; or 2) combined clinical and pathomic features.

RESULTS
A total of 84 patients with median age at diagnosis of 8.61 years (range 0.31-21.72), and median OS of 45.6 months (range 0.76-195.87)) were included in the study. A survival model built using only clinical features yielded a concordance index (c-index) of 0.76 compared to actual outcomes (stratification: p&lt;0.001). Combining clinical and high-performing pathomic features, however, yielded the best performance of the model, showing disparate outcomes between low-, medium- and high-risk groups (p&lt;0.001) with resultant c-index of 0.85.

CONCLUSION
Our results highlight the utility of pathomics analysis in predicting survival in patients with pediatric medulloblastoma, which can be used to guide treatment strategy. Further work will aim to perform our analysis on an unseen validation set to improve its performance and applicability in the clinical realm.
SPCR-11 DEMOGRAPHIC DISPARITIES AND PROGNOSTIC FACTORS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A SEER DATABASE ANALYSIS
Authors: Ramesh Nithya , Baralo Bohdan , Chitra Shanjeev Kumar Rajeshkumar , Naik Mansi , Chhibber Sherley , Thirumaran Rajesh 
Published: August 2023

Abstract
Accounting for 3-4% of all central nervous system malignancies, primary CNS lymphoma (PCNSL) is a rare but aggressive form of extranodal non-Hodgkin lymphoma. Although recent studies have demonstrated an overall decline in the incidence, certain demographics are known to be more affected than others. We reviewed the queried Surveillance, Epidemiology, and End Results (SEER) database, 17 registries, Nov 2021 sub (2000-2019) for lymphoid neoplasm recode 2021 revision with primary site codes C69.1-69.4, C69.9-70.1, C70.9-72.5, C72.8-72.9. Patients of unknown race, ethnicity, and stage of the disease were excluded. We used Cox proportional hazard regression to assess the determinants of overall survival (OS) and cause-specific survival (CSS). Significance level was set to 0.05. Our search included 5910 patients. The mean age at diagnosis was 61.8 ± 15.8 years. Males accounted for 53.67% of the patients. Racial demographics showed a predominance of Whites (66.1%), followed by Hispanics (15.6%), Asian/pacific islanders (10.3%), Blacks (7.4%), and American Indians/Alaska Natives (0.45%). Most common histology was diffuse large B-cell lymphoma (67.74%). Most patients were diagnosed at stage I (76.5%), followed by stage IV (19.7%) of the disease. Older patients had worse OS (HR 1.03 [1.027;1.032]) and CSS (HR 1.021 [1.018;1.024]). Females had better OS 0.853 [0.803;0.9059]) and CSS (HR 0.8871 [0.8145;0.966]) compared to males. Indolent (follicular and marginal zone) lymphomas were associated with better OS (HR 0.3169 [0.2647-0.3759]) and CSS (HR 0.4265 [0.3494-0.5152]) compared to large B-cell lymphoma. Black patients had worse OS (1.608 [1.421-1.813]) and CSS (HR 1.385 [1.165-1.635]). While Hispanic ethnicity did not influence OS, it was associated with worse CSS (1.158 [1.025;1.304]). Stage at diagnosis did not have a statistically significant association with survival. These results suggest a need for additional research targeting high-risk demographics to develop tailored treatments, enhance care accessibility, and address possible inequities in the management of PCNSL.
SYST-23 CDK1 AS AN INDEPENDENT PROGNOSTIC INDICATOR AND POTENTIAL THERAPEUTIC TARGET IN GLIOMA
Authors: Wang Yu , Zhou Huandi , Han Xuetao , Zhang Dongdong , Hou Liubing , Xue Xiaoying , Li Yuehong 
Published: August 2023

Abstract
Glioma is the most common primary malignant tumor in the brain with extremely poor prognosis. Firstly, in order to find the important genes and mechanisms involved in the initiation and progression of glioma, we selected four groups of gene expression profiles from GEO dataset include GSE29796, GSE4290, GSE50161 and GSE7696 for comprehensive data analysis. We identified 360 differentially expressed genes (DEGs), then we screened out core gene which is CDK1 by protein-protein interaction (PPI) network analysis. So as to clarify whether CDK1 is an independent prognostic factor for glioma, we performed expression analysis and prognostic analysis. Meanwhile, in order to verify the expression and survival of CDK1, we used Western blot to detect CDK1 expression of 15 glioma specimens and corresponding adjacent tissues. Moreover, we divided the expression values of CDK1 gene in the CGGA database into high and low groups based on the median for differential expression analysis. Finally, to explore the molecular mechanism of action of CDK1 in gliomas, we conducted gene ontology (GO) enrichment analysis and gene collection enrichment analysis (GSEA),and performed gene co-expression analysis. The results revealed that the expression level of CDK1 in glioma was significantly higher than normal tissues, its high expression was closely associated with poor survival of glioma. And the prognostic analysis showed that CDK1 was an independent prognostic index of glioma. Through the mechanism analysis of GO and GSEA, it is demonstrated that CDK1 plays an important role in the mitosis cell cycle of glioma, and inhibiting the expression of CDK1 can affect the proliferation of glioma cells. Coexpression analysis displayed that the high expression of PCNA, MCM2, MCM3, MCM4, MCM6, PLK1, TTK and MAD2L1 are also correlated to the poor survival and prognosis of glioma. Hence CDK1 is an independent prognostic factor and potential therapeutic target of glioma. Furthermore ,we can affect the proliferation of glioma cells through inhibiting the expression of CDK1.
TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2+ BREAST CANCER WITH THE ADDITION OF TUCATINIB (BRIDGET)
Authors: Van Swearingen Amanda , Sammons Sarah , Noteware Laura , Bagegni Nusayba , Moulton Kelly , Threatt Stevie , Jaggers Denise , Shea Shannon , Lipp Eric , Riley Erin , Jung Sin-Ho , Broadwater Gloria , Ross Masey , Strickland Kimberly , Beyer Sasha , Conlin Alison , Morikawa Aki , Murthy Rashmi , Anders Carey 
Published: August 2023

Abstract
Despite trastuzumab-based therapy, up to half of patients with HER2+ metastatic breast cancer (MBC) will develop brain metastases (BrM). First-line therapy for HER2+ MBC, taxane/trastuzumab/pertuzumab (TP), demonstrates poor brain permeability. Isolated brain relapse with stable/absent extracranial disease remains a clinical problem in both the adjuvant and metastatic settings, and current guidelines recommend continuing current systemic therapy following local therapy. Tucatinib, a brain-penetrable HER2-inhibitor, when added to trastuzumab and capecitabine improves intracranial PFS and OS in patients with stable/active HER2+ BrMs. We hypothesize that adding tucatinib to TP or T-DM1 in patients with HER2+ MBC with isolated brain relapse or progression could delay or prevent the development of further intracranial lesions and improve OS. BRIDGET (NCT05323955) is a single arm, phase II study of tucatinib added to TP or T-DM1 after local therapy in patients with isolated brain relapse or progression. A total of 48 patients at 9 U.S. sites through HCRN with HER2+ MBC will be enrolled after 1st or 2nd BrM relapse/progression within 8 weeks of local therapy. Patients must currently be receiving TP or T-DM1 in the metastatic setting, or adjuvant trastuzumab-based or T-DM1 therapy with isolated brain recurrence. Extracranial disease must be stable per RECISTv1.1 or absent. Patients will receive tucatinib added to their current therapy. The primary objective is intracranial PFS compared to a historical control (H0: historical iPFS &lt;5 months (mos), HA: iPFS &gt;8 mos) of the HER2CLIMB trial. In these patients, median time from brain progression to second progression/death was 7.6 mos with tucatinib versus 3.1 mos in the control arm. Secondary endpoints include PFS by RECISTv1.1, PFS of extracranial disease, locally treated versus new distant intracranial metastasis PFS, site of first progression, OS, and toxicity. Collection of correlative specimens and patient-reported outcomes (FACT-BR, FACIT-Fatigue) are also included.
Symbolic incentives and the recruitment of volunteers for citizen science projects
Authors: Cicognani Simona , Stein Sebastian , Tonin Mirco , Vlassopoulos Michael 
Published: August 2023

Abstract
The provision of activities with external benefits that rely on voluntary contributions may often fall below societal needs. In this article, we focus on such contributions to a citizen science project (the World Community Grid) in which members of the general public are asked to offer unused computer power to advance cutting-edge scientific research. We investigate the role played by symbolic awards in stimulating existing contributors to recruit new contributors for this project. The recruitment campaign we study introduces badges for referrals (visible on each user’s public profile page) varying, across randomized treatment groups, the threshold of successful referrals needed to receive these badges. We find that these symbolic incentives are effective in boosting referrals, and more so when the minimum threshold for achieving symbolic awards is higher. However, the overall effect of the incentives is quite modest, highlighting the challenges of running referral campaigns for the recruitment of volunteers.
Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
Authors: Olsen Margaret A , Keller Matthew R , Stwalley Dustin , Yu Holly , Dubberke Erik R 
Published: August 2023

Abstract

Background
Although increased occurrence of septicemia in persons with Clostridioides difficile infection (CDI) has been reported, incidence rates and risk of septicemia and urinary tract infection (UTI) after CDI are unclear.

Methods
The first episode of CDI was identified using 2011–2017 MarketScan and CMS Medicare data and CDI cases categorized by standard surveillance definitions. Uninfected persons were frequency matched 4:1 to cases by the CDI case surveillance definition. Multivariable Cox proportional hazards models were used to identify risk factors for septicemia and UTI within 90 days of CDI onset, accounting for the competing risk of death in the Medicare population.

Results
The incidence of septicemia was highest after hospital-onset CDI in the Medicare, younger commercial, and younger Medicaid populations (25.5%, 15.7%, and 19.5%, respectively) and lowest in those with community-associated CDI (3.8%, 4.3%, and 8.3%, respectively). In contrast, the incidence of UTI was highest in those with other healthcare facility onset CDI in all 3 populations (32.1%, 24.2%, and 18.1%, respectively). Hospital-onset CDI was associated with highest risk of septicemia compared with uninfected controls in all 3 populations. In the younger populations, risk of septicemia was more uniform across the CDI surveillance definitions. The risk of UTI was significantly higher in all CDI surveillance categories compared to uninfected controls, and among CDI cases it was lowest in those with community-associated CDI.

Conclusions
The incidence of septicemia is high after CDI, particularly after hospital-onset infection. Additional preventive measures are needed to reduce infectious complications of CDI.
Genomic variations combined with epigenetic modifications rewire open chromatin in rice
Authors: Li Mengqi , Feng Yilong , Han Qi , Yang Ying , Shi Yining , Zheng Dongyang , Zhang Wenli 
Published: August 2023

Abstract
Cis-regulatory elements (CREs) fine-tune gene transcription in eukaryotes. CREs with sequence variations play vital roles in driving plant or crop domestication. However, how global sequence and structural variations (SVs) are responsible for multilevel changes between indica and japonica rice (Oryza sativa) is still not fully elucidated. To address this, we conducted multiomic studies using MNase hypersensitivity sequencing (MH-seq) in combination with RNA sequencing (RNA-seq), chromatin immunoprecipitation sequencing (ChIP-seq), and bisulfite sequencing (BS-seq) between the japonica rice variety Nipponbare (NIP) and indica rice variety 93-11. We found that differential MNase hypersensitive sites (MHSs) exhibited some distinct intrinsic genomic sequence features between NIP and 93-11. Notably, through MHS–genome-wide association studies (GWAS) integration, we found that key sequence variations may be associated with differences of agronomic traits between NIP and 93-11, which is partly achieved by MHSs harboring CREs. In addition, SV-derived differential MHSs caused by transposable element (TE) insertion, especially by noncommon TEs among rice varieties, were associated with genes with distinct functions, indicating that TE-driven gene neo- or subfunctionalization is mediated by changes of chromatin openness. This study thus provides insights into how sequence and genomic SVs control agronomic traits of NIP and 93-11; it also provides genome-editing targets for molecular breeding aiming at improving favorable agronomic properties.
Evaluation of a therapist-guided virtual psychological pain management program when provided as routine care: a prospective pragmatic cohort study
Authors: Dear Blake F , Walker Jennie , Karin Eyal , Asrianti Lia , England Jonathan , Feliciano Ivy , Bisby Madelyne A , Nielssen Olav , Kayrouz Rony , Cross Shane , Staples Lauren G , Hadjistavropoulos Heather D , Titov Nickolai 
Published: August 2023

Abstract

Introduction
Numerous randomized controlled trials have evaluated the outcomes of internet-delivered psychological pain management programs (PMPs) as a way of increasing access to care for people with chronic pain. However, there are few reports of the effectiveness of these PMPs when provided as part of routine care.

Methods
The present study sought to report the clinical and demographic characteristics of users (n = 1367) and examine the effectiveness of an established internet-delivered psychological PMP program in improving several pain-related outcomes, when offered at a national digital mental health service over a 5-year period. It also sought to comprehensively explore predictors of treatment commencement, treatment completion, and clinical improvement.

Results
Evidence of clinical improvements (% improvement; Hedges g) were found for all outcomes, including pain interference (18.9%; 0.55), depression (26.1%; 0.50), anxiety (23.9%; 0.39), pain intensity (12.8%; 0.41), pain self-efficacy (-23.8%; -0.46) and pain-catastrophizing (26.3%; 0.56). A small proportion of users enrolled but did not commence treatment (13%), however high levels of treatment completion (whole treatment = 63%; majority of the treatment = 75%) and satisfaction (very satisfied = 45%; satisfied = 37%) were observed among those who commenced treatment. There were a number of demographic and clinical factors associated with commencement, completion and improvement, but no decisive or dominant predictors were observed.

Discussion
These findings highlight the effectiveness and acceptability of internet-delivered psychological PMPs in routine care and point to the need to consider how best to integrate these interventions into the pathways of care for people with chronic pain.